186 related articles for article (PubMed ID: 37274773)
1. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
[No Abstract] [Full Text] [Related]
2. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
3. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
5. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
Yoo TK; Kang J; Lee A; Chae BJ
Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
[TBL] [Abstract][Full Text] [Related]
6. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J
Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
[TBL] [Abstract][Full Text] [Related]
8. Subclassifying triple-negative breast cancers and its potential clinical utility.
Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
[TBL] [Abstract][Full Text] [Related]
9. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
10. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
[TBL] [Abstract][Full Text] [Related]
12. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
13. Ultrasonographic appearance of triple-negative invasive breast carcinoma is associated with novel molecular subtypes based on transcriptomic analysis.
Li JW; Li N; Jiang YZ; Liu YR; Shi ZT; Chang C; Shao ZM
Ann Transl Med; 2020 Apr; 8(7):435. PubMed ID: 32395479
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity.
Ding YC; Steele L; Warden C; Wilczynski S; Mortimer J; Yuan Y; Neuhausen SL
Oncotarget; 2019 Jan; 10(2):198-208. PubMed ID: 30719214
[TBL] [Abstract][Full Text] [Related]
15. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
[TBL] [Abstract][Full Text] [Related]
17. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
19. Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer.
Lin L; Li H; Wang X; Wang Z; Su G; Zhou J; Sun S; Ma X; Chen Y; You C; Gu Y
Cancer Med; 2023 Dec; 12(24):21639-21650. PubMed ID: 38059408
[TBL] [Abstract][Full Text] [Related]
20. Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer.
Müller M; Güth U; Varga Z; Reeve K; Bjelic-Radisic V; Fleisch M; Tausch CJ; Elfgen C
Anticancer Res; 2020 Apr; 40(4):2125-2131. PubMed ID: 32234905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
